Australia markets closed

Biostage, Inc. (BSTG)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
6.460.00 (0.00%)
At close: 02:29PM EST
Full screen
Trade prices are not sourced from all markets
Previous close6.46
Open6.35
Bid0.00 x 0
Ask0.00 x 0
Day's range6.35 - 6.46
52-week range3.50 - 9.00
Volume1,695
Avg. volume1,273
Market cap75.219M
Beta (5Y monthly)-0.92
PE ratio (TTM)N/A
EPS (TTM)-0.89
Earnings date28 Mar 2023 - 03 Apr 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Biostage Amends CEO Employment Agreement

    Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and the airway resulting from cancer, trauma or birth defects, today announced that effective as of January 11, 2023, Biostage, Inc. (the Company) entered into an Amended and Restated Employment Agreement (the Amended Agreement) with David Green, the Chief Executive Officer of the Company, to remove the Interi

  • PR Newswire

    Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer

    Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and the airway resulting from cancer, trauma or birth defects, today announced that it had selected IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, as the contract research organization (CRO) to manage its first clinical

  • PR Newswire

    New Publication Demonstrates Rapid Esophageal Regeneration using the Biostage Esophageal Implant

    Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience repairing the esophagus after the cancer in the patient's esophagus had been surgically removed* and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today announced the publication of a paper in the peer-reviewed Journal of Immunology and Regenerative Medicine that describes the earl